Evidence map›Paper›PMID 36662447›Full record

ArticleChemistry (Weinheim an der Bergstrasse, Germany)2023

A Bioactive Synthetic Outer-Core Oligosaccharide Derived from a Klebsiella pneumonia Lipopolysaccharide for Bacteria Recognition.

Dushen Chen, Akhilesh K Srivastava, Justyna Dubrochowska, Lin Liu, Tiehai Li, Joseph P Hoffmann, Jay K Kolls, Geert-Jan Boons

Open access · hybridAbstract read
In one paragraph

Article in Chemistry (Weinheim an der Bergstrasse, Germany), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.2field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Materials today. Bio · 2026
    Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Serum antibody screening using glycan arrays.Chemical Society reviews · 2024
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Dushen ChenDepartment of Chemical Biology and Drug Discovery, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, 3584 CG, Utrecht, The Netherlands.
Akhilesh K SrivastavaDepartment of Medicine and Pediatrics, Tulane School of Medicine, New Orleans, LA, USA.
Justyna DubrochowskaDepartment of Chemical Biology and Drug Discovery, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, 3584 CG, Utrecht, The Netherlands.
Lin LiuComplex Carbohydrate Research Center, University of Georgia, Athens, GA 30602, USA.
Tiehai LiComplex Carbohydrate Research Center, University of Georgia, Athens, GA 30602, USA.
Joseph P HoffmannDepartment of Medicine and Pediatrics, Tulane School of Medicine, New Orleans, LA, USA.
Jay K KollsDepartment of Medicine and Pediatrics, Tulane School of Medicine, New Orleans, LA, USA.
Geert-Jan BoonsDepartment of Chemical Biology and Drug Discovery, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, 3584 CG, Utrecht, The Netherlands.ORCID http://orcid.org/0000-0003-3111-5954
Tulane University · USUniversity of Georgia · USUtrecht University · NL

Funding

Training in CD4 T-cell Lung ImmunityR35HL139930 · NHLBI · TULANE UNIVERSITY OF LOUISIANA · PI KOLLS, JAY K · 2018 to 2024
$6.3M
Improved Therapeutics and Diagnostics for PneumocystisPneumoniaR01AI120033 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI JAY K KOLLS · 2016 to 2026
$4.8M
NHLBI NIH HHS R35 HL139930NIAID NIH HHS R01 AI120033NIH HHS R35HL139930 and R01AI120033
6 · The paper itself

Abstract

There is an urgent need for new treatment options for carbapenem-resistant Klebsiella pneumoniae (K. pneumoniae), which is a common cause of life-threatening hospital- and community-acquired infections. Prophylactic or therapeutic vaccination may offer an approach to control these infections, however, none has yet been approved for human use. Here, we report the chemical synthesis of an outer core tetra- and pentasaccharide derived from the lipopolysaccharide of K. pneumoniae. The oligosaccharides were equipped with an aminopentyl linker, which facilitated conjugation to the carrier proteins CRM

Indexed as

LipopolysaccharidesPneumoniaAnimalsGlycoconjugatesHumansKlebsiella pneumoniaeMiceOligosaccharidesGlycoconjugatesLipopolysaccharidesOligosaccharidesconjugationglycoconjugateglycosylationoligosaccharidesvaccine

Identifiers

PMID36662447
PMCPMC10159924
OpenAlexW4317567377

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.